Inge Marie Svane, professor with a broad experience within cancer immunology and immunotherapy
Inge Marie Svane is professor in Clinical cancer immune therapy and director of the translational research centre, Center for Cancer Immune Therapy (CCIT) located at Herlev Hospital. She is also a co-founder of IO Biotech Iand is an advisor for several large pharma companies.
Center for Cancer Immune Therapy is a nationally unique research center focused on cancer immunology and immunotherapy. Founded in 2006, CCIT has rapidly gained international recognition and is now among the world-leading centers in the discovery and clinical implementation of novel cancer immunotherapies. CCIT has initiated over 25 clinical trials to test novel technologies developed internally at CCIT.
With CCIT’s activities, over 300 Danish patients have had access to innovative technologies which, in several cases, resulted in a cure for their cancer. Many clinical trials are currently open for enrolment at CCIT, with patients referred from the whole of Denmark.
Inge Marie Svane has a publication list of 141 scientific publications on cancer immuneotherapy which during the past 10 years has emerged as the most effective treatment to treat multiple types of cancer, such as lung cancer and melanoma.
Mai-Britt Zocca, biotech CEO with a strong focus on translational immunology
Mai-Britt Zocca is Chief Executive Officer (CEO) of IO Biotech. She has participated in founding and co-founding of several biotech spinouts. She is a member of the BoD of VAR2 Pharmaceuticals and has held several executive positions in the industry. Mrs. Zocca holds a PhD in tumor immunology and a Master Sc. in Biochemistry. She received her PhD from the Institute of Medical Microbiology and Immunology, University of Copenhagen, and the NIH, National Cancer Institute (NCI), Bethesda, Maryland, USA.
Mai-Britt Zocca has more than 15 years of experience in translational immunology (Immuno Oncology) and has published more than 25 articles in peer reviewed international journals. Furthermore, she is an inventor of several patents.
Mai-Britt Zocca has focused her work on translational immunology especially for the development of immunotherapies for cancer diseases. Mai-Britt Zocca has been involved in several clinical studies and is also focused on biomarker discovery within the field of immunotherapy and participates in a taskforce consisting of several EU and US clinical departments and the FD